Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the impacts of immunotherapy on outcomes for certain patients with non–small cell lung cancer.
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the impacts of immunotherapy on outcomes for certain patients with non–small cell lung cancer.
Transcript
How has the growing list of immunotherapy options impacted the lung cancer treatment paradigm?
If you look at cancer survival figures going back to around 2017, so 5 or 6 years ago, we've been seeing an annual reduction in cancer mortality in the United States. And, interestingly, if you look at the cancers that are leading the reduction in cancer mortality, it's principally 2 diseases that 20 or 30 years ago were felt to be diseases that do not get any significant benefit from treatment. It's melanoma and non–small cell lung cancer, the disease we're talking about today.
Part of it is leveraging the immune system to mount an immune response specifically against the patient's tumor. The development of these PD-1/PD-L1 inhibitors as well as the CTLA-4 inhibitors, has really opened up the concept that a significant minority of patients can have very significant and very durable responses, meaning they last a long time—sometimes out to 5 years or so. And then, we're beginning to question, "Are these patients cured of their cancer because of the immunotherapy?"
Now, I specifically said this is in a minority of patients, so it's important to think of this as a foot in the door if you will. We understand that our initial targets of PD-1 and CTLA-4 do change the outcome of patients and are leading to a reduction in cancer mortality, and we need to build on that. We need to understand other targets, and there are a number of investigational agents ongoing in this space in the form of clinical trials. And so we need to wait and see what will work and what will not work.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More